Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:21:21 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



News for U:AFMD from 2023-05-04 to 2024-05-03 - 35 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-24 04:05U:AFMDNews ReleaseAffimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
2024-03-28 06:30U:AFMDNews ReleaseAffimed Reports 2023 Financial Results and Operational Progress
2024-03-21 06:30U:AFMDNews ReleaseAffimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
2024-03-06 06:30U:AFMDNews ReleaseAffimed Announces 1-for-10 Reverse Stock Split
2024-01-08 16:05U:AFMDNews ReleaseAffimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
2024-01-08 08:00U:AFMDNews ReleaseAffimed Announces Leadership Change and ‚  Organizational Restructuring
2024-01-03 06:30U:AFMDNews ReleaseAffimed Announces Sale of Wholly-Owned Subsidiary AbCheck
2023-12-11 06:02U:AFMDNews ReleaseAffimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
2023-12-11 06:00U:AFMDNews ReleaseAffimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
2023-12-04 06:30U:AFMDNews ReleaseAffimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
2023-11-14 06:30U:AFMDNews ReleaseAffimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
2023-11-09 06:30U:AFMDNews ReleaseAffimed Announces Acimtamig as International Nonproprietary Name for AFM13
2023-11-07 06:30U:AFMDNews ReleaseAffimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
2023-11-03 12:05U:AFMDNews ReleaseAffimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
2023-11-02 09:05U:AFMDNews ReleaseAffimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
2023-11-01 06:30U:AFMDNews ReleaseAffimed to Participate in Upcoming Investor Conferences
2023-10-04 06:30U:AFMDNews ReleaseAffimed Announces Listing Transfer to Nasdaq Capital Markets
2023-09-27 09:05U:AFMDNews ReleaseAffimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
2023-09-21 06:30U:AFMDNews ReleaseAffimed to Present at the Cantor Global Healthcare Conference 2023
2023-09-12 06:30U:AFMDNews ReleaseAffimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK ‚ ® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
2023-09-07 06:30U:AFMDNews ReleaseAffimed to Present at the H.C. Wainwright Annual Global Investment Conference
2023-08-22 05:00U:AFMDNews ReleaseAffimed Announces Publication in the Journal mAbs on Leveraging ‚  FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability
2023-08-10 06:30U:AFMDNews ReleaseAffimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
2023-08-03 06:30U:AFMDNews ReleaseAffimed to Report Second Quarter 2023 Financial Results & ‚  Corporate Update on August 10, 2023
2023-07-31 17:05U:AFMDNews ReleaseAffimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech ¢ € ™s SNK01 NK Cells
2023-06-22 06:30U:AFMDNews ReleaseAffimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
2023-06-09 17:59U:AFMDNews ReleaseAffimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)
2023-06-03 09:00U:AFMDNews ReleaseAffimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan
2023-05-30 06:30U:AFMDNews ReleaseAffimed to Present at the 2023 Jefferies Healthcare Conference
2023-05-25 17:00U:AFMDNews ReleaseAffimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology
2023-05-23 06:30U:AFMDNews ReleaseAffimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress
2023-05-23 06:15U:AFMDNews ReleaseAffimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
2023-05-22 06:30U:AFMDNews ReleaseAffimed Announces Annual General Meeting of Shareholders
2023-05-16 06:30U:AFMDNews ReleaseAffimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023
2023-05-11 10:05U:AFMDNews ReleaseAffimed Announces Abstracts at the Annual Meeting of the European Hematology Association